CRISPR Therapeutics AG (NASDAQ:CRSP) is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood. BofA is Bullish on CRISPR Therapeutics AG (CRSP) On January 22, 2026, TheFly disclosed that Alec Stranahan, a BofA analyst. It reduced the price objective for CRISPR Therapeutics AG (NASDAQ:CRSP) from $90 to$89 and retained a buy rating. Casgevy’s 2026 projections were slightly lowered as a result of the modification. Based on an earnings preview paper covering the biotechnology group, BofA still pro ...